Inhibrx Biosciences announced preliminary efficacy and safety data from its Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for advanced colorectal adenocarcinoma (CRC). Efficacy was assessed in 10 of 13 patients, demonstrating one complete response (CR), three partial responses (PR), and six cases of stable disease (SD).
Durable disease control, defined as lasting at least 180 days, was observed in 46.2% of patients, with a median progression-free survival (PFS) of 7.85 months. Notably, the patient achieving a CR had undergone three prior lines of therapy, and two PRs occurred in patients who had failed prior FOLFIRI-based treatments.
Ozekibart-related treatment-emergent adverse events (TEAEs) were reported in 84.6% of patients, with most being grade 1 or 2 in severity, and Grade ">=3" TEAEs observed in 30.8% of patients. Encouraged by these results, Inhibrx initiated a new expansion cohort to enroll up to 50 patients, with data anticipated in Q3 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.